Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (4): 610-613. doi: 10.19723/j.issn.1671-167X.2020.04.002

Previous Articles     Next Articles

  

  • Received:2020-02-27 Online:2020-08-18 Published:2020-08-06

RICH HTML

  

CLC Number: 

  • R737.11

Figure 1

Percutaneous nephroscopy for renal pelvis tumor 3A, appearance of the tumor under flexible ureteroscopy; 3B, laser resection of the tumor; 3C, remove the tumor with stone basket; 3D, burn the tumor base with laser; 3E, check the residual tumor with the narrow band imaging (NBI)."

Figure 2

Small tumor under the narrow band imaging (NBI), the tumor is brown and appears as “frog eggs” "

Figure 3

Resection of the tumor by flexible ureteroscopy"

Figure 4

During the operation of percuteanous nephroscopy combined with flexible ureteroscopy, flexible ureteroscope can monitor the puncture process of the percutaneous nephroscope, and deal with the places that difficult to be observed by the percutaneous nephroscope (4A), the percutaneous nephroscope can deal with the large volume tumor of the inferior renal calyx (4B) "

[1] Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)[J]. World J Urol, 2017,35(3):379-387.
pmid: 27604375
[2] Cutress ML, Stewart GD, Tudor EC, et al. Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience[J]. J Urol, 2013,189(6):2054-2060.
pmid: 23228378
[3] Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2017 update[J]. Eur Urol, 2018,73(1):111-122.
doi: 10.1016/j.eururo.2017.07.036 pmid: 28867446
[4] Mandalapu RS, Remzi M, de Reijke TM, et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma[J]. World J Urol, 2017,35(3):355-365.
[5] Jung H, Giusti G, Fajkovic H, et al. Consultation on UTUC, Stockholm 2018: aspects of treatment[J]. World J Urol, 2019,37(11):2279-2287.
[6] Browne BM, Stensland KD, Moynihan MJ, et al. An analysis of staging and treatment trends for upper tract urothelial carcinoma in the National Cancer Database[J]. Clin Genitourin Cancer, 2018,16(4):e743-e750.
[7] 肖博, 肖春雷, 马潞林, 等. 经皮肾镜技术治疗上尿路肿瘤的初步经验[J]. 中华泌尿外科杂志, 2011,32(6):383-386.
[8] Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: Is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy?[J]. Urology, 2009,73(1):27-31.
pmid: 18929398
[9] 郝一昌, 肖春雷, 刘余庆, 等. 经皮肾镜术治疗上尿路肿瘤术后通道种植1例报告及相关问题的探讨[J]. 临床泌尿外科杂志, 2017,32(1):70-73.
[10] 邱敏, 颜野, 田晓军, 等. 窄带成像技术辅助经尿道膀胱肿瘤切除术[J]. 中国微创外科杂志, 2018,18(10):888-890.
[11] 郝一昌, 肖春雷, 刘可, 等. 窄带成像技术结合输尿管软镜在上尿路尿路上皮肿瘤诊断、治疗和随访中的应用研究[J]. 中华外科杂志, 2018,56(3):222-226.
[12] Wen J, Ji ZG, Li HZ. Treatment of upper tract urothelial carcinoma with ureteroscopy and thulium laser: a retrospective single center study[J]. BMC Cancer, 2018,18(1):196.
doi: 10.1186/s12885-018-4118-y
[13] Foerster B, D’Andrea D, Abufaraj M, et al. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature[J]. Urol Oncol, 2019,37(7):430-436.
doi: 10.1016/j.urolonc.2019.02.004 pmid: 30846387
[14] 徐楚潇, 郝一昌, 肖春雷, 等. 经皮肾镜技术联合二期输尿管软镜手术治疗孤立肾上尿路肿瘤1例[J]. 临床泌尿外科杂志, 2017,32(2):161-162.
[15] 郝一昌, 陈昆, 刘余庆, 等. 输尿管软镜下钬激光切除术治疗肾盂癌6例报道及文献复习[J]. 北京大学学报(医学版), 2018,50(5):816-821.
[1] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[2] Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635.
[3] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[4] Kewei CHEN,Shaohui DENG,Zhuo LIU,Hongxian ZHANG,Lulin MA,Shudong ZHANG. Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 326-331.
[5] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[6] Min QIU,You-long ZONG,Bin-shuai WANG,Bin YANG,Chu-xiao XU,Zheng-hui SUN,Min LU,Lei ZHAO,Jian LU,Cheng LIU,Xiao-jun TIAN,Lu-lin MA. Treatment outcome of laparoscopic partial nephrectomy in patients with renal tumors of moderate to high complexity [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 833-837.
[7] 聪 田,军 刘,波 杨,佳佳 乔,晓波 黄,清泉 许. [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 948-952.
[8] Qi SHEN,Yi-xiao LIU,Qun HE. Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis [J]. Journal of Peking University (Health Sciences), 2023, 55(2): 276-282.
[9] Quan ZHANG,Hai-feng SONG,Bing-lei MA,Zhe-nan ZHANG,Chao-hui ZHOU,Ao-lin LI,Jun LIU,Lei LIANG,Shi-yu ZHU,Qian ZHANG. Pre-operative prognostic nutritional index as a predictive factor for prognosis in non-metastatic renal cell carcinoma treated with surgery [J]. Journal of Peking University (Health Sciences), 2023, 55(1): 149-155.
[10] 利群 周,纯如 徐. [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 587-591.
[11] 鑫 周,文智 李. [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 595-598.
[12] Er-shu BO,Peng HONG,Yu ZHANG,Shao-hui DENG,Li-yuan GE,Min LU,Nan LI,Lu-lin MA,Shu-dong ZHANG. Clinicopathological features and prognostic analysis of papillary renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 615-620.
[13] Min QIU,Yan-yan LIAN,Min LU,Bin-shuai WANG,Xiao-jun TIAN,Jian LU,Cheng LIU,Shu-dong ZHANG,Min JIANG,Lu-lin MA. Treatment and prognosis of multiple primary malignant neoplasms complicated with renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 680-685.
[14] Yu TIAN,Xiao-yue CHENG,Hui-ying HE,Guo-liang WANG,Lu-lin MA. Clinical and pathological features of renal cell carcinoma with urinary tract tumor thrombus: 6 cases report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 928-932.
[15] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!